advertisement
Prasanna G 58
Showing records 1 to 25 | Display only abstracts from Prasanna G in IGR 18-1119812 Complement Factor B Inhibition or Deletion Is Not Sufficient to Prevent Neurodegeneration in a Murine Model of Glaucoma
Dolan K; Liao SM; Crowley M; Xiang C; Adams CM; Brown A; Vo N; Chen A; Delgado O; Buchanan N; Guo C; Prasanna G
Journal of Ocular Pharmacology and Therapeutics 2024; 40: 524-535 (IGR: 25-1)
90249 Understanding metabolism related differences in ocular efficacy of MGV354
Dumouchel JL; Argikar UA; Adams CM; Prasanna G; Ehara T; Kim S; Breen C; Mogi M
Xenobiotica; the fate of foreign compounds in biological systems 2021; 51: 5-14 (IGR: 21-3)
80953 Using Healthcare Databases to Refine Understanding of Exploratory Associations Between Drugs and Progression of Open-Angle Glaucoma
Wang SV; Li N; Rice DS; Grosskreutz CL; Dryja TP; Prasanna G; Lii J; Gagne JJ
Clinical Pharmacology and Therapeutics 2019; 106: 874-883 (IGR: 20-3)
79518 Binding of a glaucoma-associated myocilin variant to the αB-crystallin chaperone impedes protein clearance in trabecular meshwork cells
Lynch JM
Journal of Biological Chemistry 2018; 293: 20137-20156 (IGR: 20-2)
79741 Glaucoma - Next Generation Therapeutics: Impossible to Possible
Adams CM
Pharmaceutical Research 2018; 36: 25 (IGR: 20-2)
79518 Binding of a glaucoma-associated myocilin variant to the αB-crystallin chaperone impedes protein clearance in trabecular meshwork cells
Li B
Journal of Biological Chemistry 2018; 293: 20137-20156 (IGR: 20-2)
79741 Glaucoma - Next Generation Therapeutics: Impossible to Possible
Stacy R; Stacy R
Pharmaceutical Research 2018; 36: 25 (IGR: 20-2)
79518 Binding of a glaucoma-associated myocilin variant to the αB-crystallin chaperone impedes protein clearance in trabecular meshwork cells
Katoli P
Journal of Biological Chemistry 2018; 293: 20137-20156 (IGR: 20-2)
79741 Glaucoma - Next Generation Therapeutics: Impossible to Possible
Rangaswamy N
Pharmaceutical Research 2018; 36: 25 (IGR: 20-2)
79518 Binding of a glaucoma-associated myocilin variant to the αB-crystallin chaperone impedes protein clearance in trabecular meshwork cells
Xiang C
Journal of Biological Chemistry 2018; 293: 20137-20156 (IGR: 20-2)
79741 Glaucoma - Next Generation Therapeutics: Impossible to Possible
Bigelow C; Grosskreutz CL
Pharmaceutical Research 2018; 36: 25 (IGR: 20-2)
79518 Binding of a glaucoma-associated myocilin variant to the αB-crystallin chaperone impedes protein clearance in trabecular meshwork cells
Leehy B; Rangaswamy N
Journal of Biological Chemistry 2018; 293: 20137-20156 (IGR: 20-2)
79741 Glaucoma - Next Generation Therapeutics: Impossible to Possible
Prasanna G
Pharmaceutical Research 2018; 36: 25 (IGR: 20-2)
79518 Binding of a glaucoma-associated myocilin variant to the αB-crystallin chaperone impedes protein clearance in trabecular meshwork cells
Saenz-Vash V; Wang YK; Lei H; Nicholson TB; Meredith E; Rice DS; Prasanna G; Chen A
Journal of Biological Chemistry 2018; 293: 20137-20156 (IGR: 20-2)
78021 A murine glaucoma model induced by rapid in vivo photopolymerization of hyaluronic acid glycidyl methacrylate
Guo C; Qu X; Rangaswamy N; Leehy B; Xiang C; Rice D; Prasanna G
PLoS ONE 2018; 13: e0196529 (IGR: 19-4)
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Stacy R; Stacy R
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Prasanna G
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Huttner K
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Ferrara L; Adams C; Adams C
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Watts J; Peace J
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Ehara T; Li B
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Wirta D; Walters T
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Yang L; Xiang C
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Sall K
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Ng CTH
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)
